Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Medivolve Inc. (COPRF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.01500.0000 (0.00%)
At close: 03:36PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0150
Open0.0149
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0150 - 0.0150
52 Week Range0.0130 - 0.2000
Volume44,661
Avg. Volume183,241
Market Cap5.869M
Beta (5Y Monthly)2.96
PE Ratio (TTM)N/A
EPS (TTM)-0.3070
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Aberdeen Disposes of Shares of Medivolve and Ceases to Be an Insider

    TORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- ABERDEEN INTERNATIONAL INC. (“Aberdeen” or the “Company”) (TSX: AAB) announces that it has sold 7,000,000 common shares of Medivolve Inc. (“Medivolve”) (NEO: MEDV) on September 22, 2022, which has resulted in Aberdeen’s ownership being reduced by 1.7% to less than 10% of the outstanding Medivolve common shares and Aberdeen ceasing to be an insider of Medivolve The Company reviews its holdings from time to time and may increase or decrease its position

  • GlobeNewswire

    Medivolve Announces Launch of Investor Awareness Campaign and Refiling of Q2 2022 Financial Statements

    TORONTO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Medivolve Inc. (“Medivolve” or the “Company”) (NEO: MEDV; OTC: COPRF; FRA: 4NC) is pleased to announce the launch of an investor marketing campaign to raise awareness of the Company in the investing community. The Company also announces that it has amended and refiled its condensed interim consolidated financial statements (the “Q2 2022 Financials”) and corresponding management’s discussion and analysis (the “Q2 2022 MDA”) for the six-month period ended

  • GlobeNewswire

    Medivolve Announces Q2 2022 Financial Results

    TORONTO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Medivolve Inc. (“Medivolve” or the “Company”) (NEO: MEDV; OTC: COPRF; FRA: 4NC), a healthcare technology company that seeks to improve the US healthcare system by leveraging a bespoke telehealth platform, clinical diagnostic network, and data driven AI to improve patient care, today announced financial results for the second quarter ended June 30, 2022. "Medivolve delivered another strong quarter of financial results, achieving a 72% increase in revenue

Advertisement
Advertisement